New PET tracer aims to light up hidden cancers

NCT ID NCT07144085

Recruiting now Diagnosis Sponsor: Yi Tian Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new radioactive tracer called 68Ga-FXX489 (NNS309) for PET/CT scans. The goal is to see if it can safely and accurately detect tumors and their spread in 30 adults with suspected cancer. Researchers will measure how the tracer moves through the body and how well it highlights cancer spots compared to standard imaging.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-FXX489 (NNS309) radiotracer
What this could lead to: If successful, this could lead to a more accurate PET/CT imaging method for detecting tumors and their spread, helping doctors diagnose cancer earlier.
What could go wrong: This is a very early Phase 1 study with only 30 participants, so it is not yet proven to work. The main goal is safety and imaging quality, not treatment, so it may not improve patient outcomes directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer colorectal cancer gastric cancer lung cancer malignant pancreatic neoplasm metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CANCER TUMOR

Contacts and locations

Locations

The First Hospital of China Medical University
RECRUITING

Shenyang, Liaoning, 110001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.